Tag: Kite Pharma

Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma

Raghuram Kadari- December 31, 2022

Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their ... Read More

Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics

Raghuram Kadari- December 24, 2022

Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for ... Read More

Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma

Raghuram Kadari- December 13, 2022

Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, ... Read More

Gilead Sciences names Lilly senior VP Christi L. Shaw as Kite CEO

pharmanewsdaily- July 12, 2019

US biopharma company Gilead Sciences has named Christi L. Shaw as the new chief executive officer of its subsidiary Kite, a California-based cell therapy company, ... Read More

Kite Car T therapy Yescarta bags FDA approval for type of lymphatic cancer

pharmanewsdaily- October 19, 2017

Yescarta FDA approval : Kite Pharma has bagged the US FDA approval for its chimeric antigen receptor T cell (CAR T) therapy Yescarta (axicabtagene ciloleucel) ... Read More